ClinicalTrials.gg
CompletedNCT01301066Updated Apr 29, 2014Results posted

A 12-Week Study Comparing Pitavastatin 4 mg vs. Pravastatin 40 mg in HIV-Infected Subjects

A Phase 4 interventional study of Pitavastatin and Pravastatin in Dyslipidemia, sponsored by Kowa Research Institute, Inc.. Completed at 35 sites in United States. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2014-04-29.

Sponsored by Kowa Research Institute, Inc. (part of Kowa Company, Ltd.) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
252
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 21 studies testing pitavastatin in Dyslipidemias — 2 open to participants now, 3 under way, none of them phase 3. pitavastatin · Dyslipidemias.

Enrollment
11th of 21
252 · median 252
Started
2010
with 1 other
Phase 4
6 of 21
none open now
Registered
11th of 21
by date
Lead sponsor
4 of 21
Kowa Research Institute, Inc.

Among the 21 studies testing pitavastatin in Dyslipidemias, this one is the 11th largest by enrollment, is one of 2 that started in 2010, is one of 6 in phase 4, and was the 11th registered.

Dyslipidemias

1,249 studies on the registry are indexed under Dyslipidemias; 177 are open to participants now.

Browse Dyslipidemias studies →

Open to participants now

2 of the 21 studies testing pitavastatin in Dyslipidemias are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About pitavastatin

pitavastatin: first FDA approval 2009 (LIVALO). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 112 Dyslipidemias studies recruiting now, 55 (49%) set no upper age limit and 36 (32%) stop at 75 or younger; 11 take children under 18; 29 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies testing pitavastatin in Dyslipidemias, or all of them as a file.
02

Study summary

A 12-Week, Randomized, Double-Blind, Active-Controlled, Parallel-Group Study.

03

Conditions studied

  • Dyslipidemia

Browse trials for

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males and females (non-pregnant, non-lactating females) 18-70 years of age, inclusive, at time of consent.
  • Both men and women of child bearing potential (i.e., not surgically sterile or defined as age >40 years without menses for ≥2 years) must agree to use at least 2 reliable forms of
  • Documented infection.

Exclusion criteria

Exclusion Criteria:

  • Homozygous familial hypercholesterolemia
  • Any conditions that may cause secondary dyslipidemia
  • History of coronary artery disease (CAD) or CAD equivalent
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
252 participants (actual)

Study arms

  • Experimental
    Pitavastatin 4 mg QD

    Drug: Pitavastatin

  • Active comparator
    Pravastatin 40 mg QD

    Drug: Pravastatin

Interventions

06

What researchers measure

Primary outcomes

  1. Change of Fasting Serum Low-density Lipoprotein Cholesterol (LDL-C) at 12 Weeks

    Time frame: 12 weeks minus baseline

07

Results

Posted Apr 29, 2014

Participant flow

Participant flow — Overall Study
MilestonePitavastatin 4 mg QDPravastatin 40 mg QD
Started126126
Completed9991
Not completed2735
Withdrew: Lost to follow-up511
Withdrew: Protocol violation87
Withdrew: Withdrawal by subject49
Withdrew: Adverse event66
Withdrew: Sponsor decision21
Withdrew: Physician decision01
Withdrew: Other20

Outcome measures

PrimaryChange of Fasting Serum Low-density Lipoprotein Cholesterol (LDL-C) at 12 Weeks
Time frame:
12 weeks minus baseline
Reported as:
Mean · mg/dL
Change of Fasting Serum Low-density Lipoprotein Cholesterol (LDL-C) at 12 Weeks
mg/dLPitavastatin 4 mg QDPravastatin 40 mg QD
Change of Fasting Serum Low-density Lipoprotein Cholesterol (LDL-C) at 12 Weeks155.1 ± 25.93154.6 ± 23.91

Adverse events

Non-serious events are listed at a 1.6% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Pitavastatin 4 mg QD—7/126 (5.6%)10/126 (7.9%)
Pravastatin 40 mg QD—3/126 (2.4%)5/126 (4%)
Most frequent serious events
Showing 10 of 15
Most frequent serious events
EventPitavastatin 4 mg QDPravastatin 40 mg QD
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders1/1260/126
Arteriosclerosis coronary arteryCardiac disorders0/1261/126
Atrial septal defectCardiac disorders1/1260/126
Cerebrovascular accidentNervous system disorders0/1261/126
Chest painCardiac disorders1/1260/126
DiverticulitisGastrointestinal disorders1/1260/126
Enterovesical fistulaGastrointestinal disorders1/1260/126
GastroenteritisGastrointestinal disorders1/1260/126
Gastroenteritis viralGastrointestinal disorders1/1260/126
Herpes dermatitisInfections and infestations1/1260/126
Most frequent other events
Most frequent other events
EventPitavastatin 4 mg QDPravastatin 40 mg QD
NauseaGastrointestinal disorders1/1263/126
FatigueGeneral disorders2/1261/126
HeadacheGeneral disorders2/1261/126
Upper abdominal painGastrointestinal disorders2/1260/126
Blood CK increasedBlood and lymphatic system disorders2/1260/126
DiarrhoeaGastrointestinal disorders2/1260/126

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Pitavastatin 4 mg QDPravastatin 40 mg QDTotal
<=18 years000
Between 18 and 65 years126126252
>=65 years000
Sex: Female, Male
Sex: Female, Male(Participants)Pitavastatin 4 mg QDPravastatin 40 mg QDTotal
Female201535
Male106111217
Region of Enrollment
Region of Enrollment(participants)Pitavastatin 4 mg QDPravastatin 40 mg QDTotal
United States126126252
08

Study locations

35 sites
  • Phoenix, Arizona, United States
  • Beverly Hills, California, United States
  • Costa Mesa, California, United States
  • Long Beach, California, United States
  • Los Angeles, California, United States
  • Newport Beach, California, United States
  • San Francisco, California, United States
  • Washington, District of Columbia, United States
  • Coral Gables, Florida, United States
  • Fort Lauderdale, Florida, United States
  • Fort Pierce, Florida, United States
  • Miami Beach, Florida, United States
  • Miami, Florida, United States
  • Tampa, Florida, United States
  • Vero Beach, Florida, United States
  • Atlanta, Georgia, United States
  • Decatur, Georgia, United States
  • Springfield, Massachusetts, United States
  • Berkley, Michigan, United States
  • St. Louis, Missouri, United States
  • Hillsborough, New Jersey, United States
  • Randolph, New Jersey, United States
  • New York, New York, United States
  • Rochester, New York, United States
  • Huntersville, North Carolina, United States
  • Addison, Texas, United States
  • Austin, Texas, United States
  • Corpus Christi, Texas, United States
  • Fort Worth, Texas, United States
  • Harlingen, Texas, United States
  • Houston, Texas, United States
  • Longview, Texas, United States
  • Annandale, Virginia, United States
  • Seattle, Washington, United States
  • Spokane, Washington, United States
09

References and documents

Publications

  • Aberg JA, Sponseller CA, Ward DJ, Kryzhanovski VA, Campbell SE, Thompson MA. Pitavastatin versus pravastatin in adults with HIV-1 infection and dyslipidaemia (INTREPID): 12 week and 52 week results of a phase 4, multicentre, randomised, double-blind, superiority trial. Lancet HIV. 2017 Jul;4(7):e284-e294. doi: 10.1016/S2352-3018(17)30075-9. Epub 2017 Apr 13. Erratum In: Lancet HIV. 2017 Jul;4(7):e283. doi: 10.1016/S2352-3018(17)30085-1. PubMed 28416195 ↗
  • Toribio M, Fitch KV, Sanchez L, Burdo TH, Williams KC, Sponseller CA, McCurdy Pate M, Aberg JA, Zanni MV, Grinspoon SK. Effects of pitavastatin and pravastatin on markers of immune activation and arterial inflammation in HIV. AIDS. 2017 Mar 27;31(6):797-806. doi: 10.1097/QAD.0000000000001427. PubMed 28252528 ↗
  • Joshi PH, Miller PE, Martin SS, Jones SR, Massaro JM, D'Agostino RB Sr, Kulkarni KR, Sponseller C, Toth PP. Greater remnant lipoprotein cholesterol reduction with pitavastatin compared with pravastatin in HIV-infected patients. AIDS. 2017 Apr 24;31(7):965-971. doi: 10.1097/QAD.0000000000001423. PubMed 28121706 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2010, a primary completion of Mar 2013 and a completion of Mar 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2014, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 18, 2011
First posted
Feb 23, 2011
Start
Dec 2010
Primary completionActual
Mar 2013
CompletionActual
Mar 2013
Results first posted
Apr 29, 2014
Last update
Apr 29, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 29, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01301066
Collaborators
Kowa Pharmaceuticals America, Inc., Eli Lilly and Company
Responsible party
Sponsor
First posted
Feb 23, 2011
Start date
Dec 2010
Primary completion
Mar 2013
Completion
Mar 2013
Results posted
Apr 29, 2014
Last update
Apr 29, 2014

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pitavastatin

Start the discussion